Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05237258 · ClinicalTrials.gov registry record · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
A NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 2,300
- Enrollment target
- 20
- Study locations
NCT05237258 is a NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 2,300 participants, above the 203-participant average among 4 other High Risk Acute Myeloid Leukemia trials with a reported enrollment target (1033% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT05237258, a NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Conditions Studied
Interventions
- BEHAVIORAL Specialty Palliative Care
- BEHAVIORAL Primary Palliative Care
Study Locations (20)
Florida
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University - Durham
Alabama
- University of Alabama - Birmingham - Birmingham
California
- Stanford University - Stanford
Colorado
- University of Colorado Denver I Anschutz Medical Campus - Denver
Georgia
- Emory University - Atlanta
Illinois
- Northwestern University - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,300 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2029-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05237258
The ClinicalTrials.gov registry entry for NCT05237258 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 4 other High Risk Acute Myeloid Leukemia trials with a reported enrollment target (1033% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with High Risk Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Specialty Palliative Care is the first listed.
NCT05237258 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Florida, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05237258 about?
NCT05237258 is a clinical study titled "Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia". This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
What is the current status of trial NCT05237258?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,300 participants. The study started on 2022-06-01. Estimated completion is 2029-04.
What conditions does trial NCT05237258 study?
This clinical trial studies the following conditions: High Risk Acute Myeloid Leukemia, Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia.
What interventions are being tested in trial NCT05237258?
The interventions under investigation include: Specialty Palliative Care (BEHAVIORAL), Primary Palliative Care (BEHAVIORAL).
Who is sponsoring clinical trial NCT05237258?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05237258 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Risk Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel Digital Application for Patients With Acute Leukemia
RECRUITING · NA
-
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
RECRUITING · Phase 1
-
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.